Markets

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $68.25, marking a -0.44% move from the previous day. This change lagged the S&P 500's daily gain of 0.22%. At the same time, the Dow added 0.7%, and the tech-heavy Nasdaq gained 0.08%.

Coming into today, shares of the HIV and hepatitis C drugmaker had gained 13.23% in the past month. In that same time, the Medical sector gained 7.58%, while the S&P 500 gained 9.27%.

GILD will be looking to display strength as it nears its nex t earnings release, which is expected to be February 4, 2019. In tha t report , analysts expect GILD to post earnings of $1.74 per share. This would mark a year-over-year decline of 2.25%. Meanwhile, our latest consensus estimate is calling for revenue of $5.52 billion, down 7.27% from the prior-year quarter.

It is also important to note the recent changes to analyst estimates for GILD. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.14% lower within the past month. GILD currently has a Zacks Rank of #4 (Sell).

Digging into valuation, GILD currently has a Forward P/E ratio of 9.96. This valuation marks a discount compared to its industry's average Forward P/E of 21.9.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 44, which puts it in the top 18% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More